{"id":154984,"date":"2025-10-31T09:15:08","date_gmt":"2025-10-31T09:15:08","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/154984\/"},"modified":"2025-10-31T09:15:08","modified_gmt":"2025-10-31T09:15:08","slug":"c-terminus-dependent-detection-of-lysosomal-alpha-synuclein-in-nigral-parkinsons-disease-human-brain-neurons-molecular-neurodegeneration","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/154984\/","title":{"rendered":"C-terminus-dependent detection of lysosomal alpha-synuclein in nigral Parkinson\u2019s disease human brain neurons | Molecular Neurodegeneration"},"content":{"rendered":"
  • \n

    Maroteaux L, Campanelli JT, Scheller RH. Synuclein – a neuron-specific protein localized to the nucleus and presynaptic nerve-terminal. J Neurosci. 1988;8:2804\u201315.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Waudby CA, Camilloni C, Fitzpatrick AWP, Cabrita LD, Dobson CM, Vendruscolo M, Christodoulou J. In-cell NMR characterization of the secondary structure populations of a disordered conformation of \u03b1-synuclein within E. coli cells. Plos One. 2013;8:e72286.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW. Neuropathology and molecular diagnosis of synucleinopathies. Mol Neurodegener. 2021;16:83.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Fusco G, De Simone A, Gopinath T, Vostrikov V, Vendruscolo M, Dobson CM, Veglia G. Direct observation of the three regions in \u03b1-synuclein that determine its membrane-bound behaviour. Nat Commun. 2014;5:3827.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V. Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023;14:176.<\/p>\n<\/li>\n

  • \n

    Vamvaca K, Volles MJ, Lansbury PT. The first N-terminal amino acids of \u03b1-synuclein are essential for \u03b1-helical structure formation and membrane binding in yeast. J Mol Biol. 2009;389:413\u201324.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Bartels T, Ahlstrom LS, Leftin A, Kamp F, Haass C, Brown MF, Beyer K. The n-terminus of the intrinsically disordered protein \u03b1-synuclein triggers membrane binding and helix folding. Biophys J. 2010;99:2116\u201324.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Xu L, Bhattacharya S, Thompson D. The fold preference and thermodynamic stability of \u03b1-synuclein fibrils is encoded in the non-amyloid-\u03b2 component region. Phys Chem Chem Phys. 2018;20:4502\u201312.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Nielsen MS, Vorum H, Lindersson E, Jensen PH. Ca2+ binding to \u03b1-synuclein regulates ligand binding and oligomerization. J Biol Chem. 2001;276:22680\u20134.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T. The precursor protein of non-A beta component of Alzheimer\u2019s disease amyloid is a presynaptic protein of the central nervous system. Neuron. 1995;14:467\u201375.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Lautenschl\u00e4ger J, Stephens AD, Fusco G, Str\u00f6hl F, Curry N, Zacharopoulou M, Michel CH, Laine R, Nespovitaya N, Fantham M, et al. C-terminal calcium binding of \u03b1-synuclein modulates synaptic vesicle interaction. Nat Commun. 2018;9:712.<\/p>\n<\/li>\n

  • \n

    Lewy FH. Paralysis agitans. I. Pathologische anatomie. Berlin: Springer; 1912.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Shahmoradian SH, Lewis AJ, Genoud C, Hench J, Moors TE, Navarro PP, Casta\u00f1o-D\u00edez D, Schweighauser G, Graff-Meyer A, Godie KN, et al. Lewy pathology in Parkinson\u2019s disease consists of crowded organelles and lipid membranes. Nat Neurosci. 2019;22:1099\u2013109.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Moors TE, Maat CA, Niedieker D, Mona D, Petersen D, Timmermans-Huisman E, Kole J, El-Mashtoly SF, Spycher L, Zago W, et al. The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson\u2019s disease brain as revealed by multicolor STED microscopy. Acta Neuropathol. 2021;142:423\u201348.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Zhang J, Li X, Li JD. The roles of post-translational modifications on alpha-synuclein in the pathogenesis of Parkinson\u2019s diseases. Front Neurosci. 2019;13:381.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang JP, Kling K, Lee M, et al. Phosphorylation of Ser-129 is the dominant pathological modification of \u03b1-synuclein in familial and sporadic Lewy body disease. J Biol Chem. 2006;281:29739\u201352.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Huang S, Mo XL, Wang JY, Ye XY, Yu HJ, Liu YH. \u03b1-Synuclein phase separation and amyloid aggregation are modulated by C-terminal truncations. FEBS Lett. 2022;596:1388\u2013400.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Zhang C, Pei YS, Zhang ZT, Xu LL, Liu XL, Jiang L, Pielak GJ, Zhou X, Liu ML, Li CG. C-terminal truncation modulates \u03b1-Synuclein\u2019s cytotoxicity and aggregation by promoting the interactions with membrane and chaperone. Commun Biol. 2022;5:798.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Suthar SK, Lee SY. Truncation or proteolysis of alpha-synuclein in Parkinsonism. Ageing Res Rev. 2023;90:101978.<\/p>\n<\/li>\n

  • \n

    Sorrentino ZA, Vijayaraghavan N, Gorion KM, Riffe CJ, Strang KH, Caldwell J, Giasson BI. Physiological C-terminal truncation of \u03b1-synuclein potentiates the prion-like formation of pathological inclusions. J Biol Chem. 2018;293:18914\u201332.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Kellie JF, Higgs RE, Ryder JW, Major A, Beach TG, Adler CH, Merchant K, Knierman MD. Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson\u2019s disease brain tissue by intact protein mass spectrometry. Sci Rep. 2014;4:5797.<\/p>\n<\/li>\n

  • \n

    Li WX, West N, Colla E, Pletnikova O, Troncoso JC, Marsh L, Dawson TM, J\u00e4k\u00e4l\u00e4 P, Hartmann T, Price DL, Lee MK. Aggregation promoting C-terminal truncation of \u03b1-synuclein is a normal cellular process and is enhanced by the familial Parkinson\u2019s disease-linked mutations. P Natl Acad Sci USA. 2005;102:2162\u20137.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. \u03b1-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4:160\u20134.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Moors TE, Mona D, Luehe S, Duran-Pacheco G, Spycher L, Mundigl O, Kaluza K, Huber S, Hug MN, Kremer T, et al. Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies. Acta Neuropathol Commun. 2022;10:82<\/p>\n<\/li>\n

  • \n

    Muntane G, Ferrer I, Martinez-Vicente M. Alpha-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience. 2012;200:106\u201319.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Beach TG, White CL, Hamilton RL, Duda JE, Iwatsubo T, Dickson DW, Leverenz JB, Roncaroli F, Buttini M, Hladik CL, et al. Evaluation of \u03b1-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol. 2008;116:277\u201388.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Drobny A, Dobert J, Kluge A, Bunk J, Schlothauer T, Zunke F, Huarcaya SP. The role of lysosomal cathepsins in neurodegeneration: mechanistic insights, diagnostic potential and therapeutic approaches. Biochim Biophys Acta Mol Cell Res. 2022;1869:119243.<\/p>\n<\/li>\n

  • \n

    Lee HJ, Khoshaghideh F, Patel S, Lee SJ. Clearance of \u03b1-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci. 2004;24:1888\u201396.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant \u03b1-synuclein by chaperone-mediated autophagy. Science. 2004;305:1292\u20135.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Mak SK, McCormack AL, Manning-Bog AB, Cuervo AM, Di Monte DA. Lysosomal degradation of alpha-synuclein in vivo. J Biol Chem. 2010;285:13621\u20139.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Wiseman JA, Murray HC, Faull R, Dragunow M, Turner CP, Dieriks BV, Curtis MA. Aggregate-prone brain regions in Parkinson\u2019s disease are rich in unique N-terminus alpha-synuclein conformers with high proteolysis susceptibility. NPJ Parkinsons Dis. 2024;10:1.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Hasegawa T, Konno M, Baba T, Sugeno N, Kikuchi A, Kobayashi M, Miura E, Tanaka N, Tamai K, Furukawa K, et al. The AAA-ATPase VPS4 regulates extracellular secretion and lysosomal targeting of alpha-synuclein. PLoS ONE. 2011;6: e29460.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Abounit S, Bousset L, Loria F, Zhu S, de Chaumont F, Pieri L, Olivo-Marin JC, Melki R, Zurzolo C. Tunneling nanotubes spread fibrillar alpha-synuclein by intercellular trafficking of lysosomes. Embo J. 2016;35:2120\u201338.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Senol AD, Samarani M, Syan S, Guardia CM, Nonaka T, Liv N, Latour-Lambert P, Hasegawa M, Klumperman J, Bonifacino JS, Zurzolo C. \u0391-synuclein fibrils subvert lysosome structure and function for the propagation of protein misfolding between cells through tunneling nanotubes. PLoS Biol. 2021;19:e3001287.<\/p>\n<\/li>\n

  • \n

    Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L. Wild type \u03b1-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem. 2008;283:23542\u201356.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Xilouri M, Brekk OR, Landeck N, Pitychoutis PM, Papasilekas T, Papadopoulou-Daifoti Z, Kirik D, Stefanis L. Boosting chaperone-mediated autophagy mitigates \u03b1-synuclein-induced neurodegeneration. Brain. 2013;136:2130\u201346.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Cuddy LK, Wani WY, Morella ML, Pitcairn C, Tsutsumi K, Fredriksen K, Justman CJ, Grammatopoulos TN, Belur NR, Zunke F, et al. Stress-induced cellular clearance is mediated by the SNARE protein ykt6 and disrupted by \u03b1-synuclein. Neuron. 2019;104:869.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Mazzulli JR, Zunke F, Isacson O, Studer L, Krainc D. \u03b1-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. P Natl Acad Sci USA. 2016;113:1931\u20136.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Puska G, Lutz MI, Molnar K, Regelsberger G, Ricken G, Pirker W, Laszlo L, Kovacs GG. Lysosomal response in relation to \u03b1-synuclein pathology differs between Parkinson\u2019s disease and multiple system atrophy. Neurobiol Dis. 2018;114:140\u201352.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Ethical and legal declaration of the Netherlands Brain Bank.\u00a0https:\/\/www.brainbank.nl\/media\/uploads\/file\/Ethical%20declaration%202019.pdf<\/a>.<\/p>\n<\/li>\n

  • \n

    BrainNet Europe Consortium – Code of Conduct.\u00a0https:\/\/www.brainbank.nl\/media\/uploads\/file\/Code-of-conduct.pdf<\/a>.<\/p>\n<\/li>\n

  • \n

    Alafuzoff I, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I, Bogdanovic N, Bugiani O, Ferrer I, Gelpi E, et al. Staging\/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe consortium. Acta Neuropathol. 2009;117:635\u201352.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, et al. National institute on aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 2012;123:1\u201311.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Altay MF, Liu AKL, Holton JL, Parkkinen L, Lashuel HA. Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders. Acta Neuropathol Commun. 2022;10:163.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Altay MF, Kumar ST, Burtscher J, Jagannath S, Strand C, Miki Y, Parkkinen L, Holton JL, Lashuel HA. Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases. Npj Parkinsons Dis. 2023;9:161.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Kovacs GG, Wagner U, Dumont B, Pikkarainen M, Osman AA, Streichenberger N, Leisser I, Verchere J, Baron T, Alafuzoff I, et al. An antibody with high reactivity for disease-associated alpha-synuclein reveals extensive brain pathology. Acta Neuropathol. 2012;124:37\u201350.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Perrin RJ, Payton JE, Barnett DH, Wraight CL, Woods WS, Ye L, George JM. Epitope mapping and specificity of the anti-alpha-synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines. Neurosci Lett. 2003;349:133\u20135.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Jakes R, Crowther RA, Lee VM, Trojanowski JQ, Iwatsubo T, Goedert M. Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein. Neurosci Lett. 1999;269:13\u20136.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Games D, Valera E, Spencer B, Rockenstein E, Mante M, Adame A, Patrick C, Ubhi K, Nuber S, Sacayon P, et al. Reducing c-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson\u2019s disease-like models. J Neurosci. 2014;34:9441\u201354.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Games D, Seubert P, Rockenstein E, Patrick C, Trejo M, Ubhi K, Ettle B, Ghassemiam M, Barbour R, Schenk D, et al. Axonopathy in an \u03b1-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal truncated \u03b1-synuclein. Am J Pathol. 2013;182:940\u201353.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Delic V, Chandra S, Abdelmotilib H, Maltbie T, Wang S, Kem D, Scott HJ, Underwood RN, Liu Z, Volpicelli-Daley LA, West AB. Sensitivity and specificity of phospho-Ser129 alpha-synuclein monoclonal antibodies. J Comp Neurol. 2018;526:1978\u201390.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Lashuel HA, Mahul-Mellier AL, Novello S, Hegde RN, Jasiqi Y, Altay MF, Donzelli S, DeGuire SM, Burai R, Magalhaes P, et al. Revisiting the specificity and ability of phospho-S129 antibodies to capture alpha-synuclein biochemical and pathological diversity. NPJ Parkinsons Dis. 2022;8:136.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, Mcart DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.<\/p>\n<\/li>\n

  • \n

    Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Posit Team. RStudio: Integrated Development Environment for R. Posit Software, PBC; 2025.<\/p>\n<\/li>\n

  • \n

    R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing; 2021. <\/p>\n<\/li>\n

  • \n

    Moors TE, Morella ML, Bertran-Cobo C, Geut H, Udayar V, Timmermans-Huisman E, Ingrassia AMT, Breve JJP, Bol J, Bonifati V, et al. Altered TFEB subcellular localization in nigral neurons of subjects with incidental, sporadic and GBA-related Lewy body diseases. Acta Neuropathol. 2024;147: 67.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Mahul-Mellier A-L, Altay MF, Maharjan N, et al. Differential role of C-terminal\u00a0truncations on alpha-synuclein pathology and Lewy body formation. npj Parkinsons\u00a0Dis. 2025;11:261.<\/p>\n<\/li>\n

  • \n

    Scheiblich H, Dansokho C, Mercan D, Schmidt SV, Bousset L, Wischhof L, Eikens F, Odainic A, Spitzer J, Griep A, et al. Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes. Cell. 2021;184:5089.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Li Y, Li P, Li R, Xu Q. Intracellular antibody delivery mediated by lipids, polymers, and inorganic nanomaterials for therapeutic applications. Adv Ther. 2020;3:2000178. <\/p>\n<\/li>\n

  • \n

    Gaston J, Maestrali N, Lalle G, Gagnaire M, Masiero A, Dumas B, Dabdoubi T, Radosevic K, Berne PF. Intracellular delivery of therapeutic antibodies into specific cells using antibody-peptide fusions.\u00a0Sci Rep. 2019;9:18688.<\/p>\n<\/li>\n

  • \n

    Abraham A, Natraj U, Karande AA, Gulati A, Murthy MRN, Murugesan S, Mukunda P, Savithri HS. Intracellular delivery of antibodies by chimeric Sesbania mosaic virus (SeMV) virus like particles. Sci Rep. 2016;6:21803.<\/p>\n<\/li>\n

  • \n

    McGlinchey RP, Lee JC. Cysteine cathepsins are essential in lysosomal degradation of \u03b1-synuclein. P Natl Acad Sci USA. 2015;112:9322\u20137.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Udayar V, Chen Y, Sidransky E, Jagasia R. Lysosomal dysfunction in neurodegeneration: emerging concepts and methods. Trends Neurosci. 2022;45:184\u201399.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    M\u00e4chtel R, Boros FA, Dobert JP, Arnold P, Zunke F. From lysosomal storage disorders to Parkinson\u2019s disease-challenges and opportunities. J Mol Biol. 2023;435:167932.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Gehrlein A, Udayar V, Anastasi N, Morella ML, Ruf I, Brugger D, von der Mark S, Thoma R, Rufer A, Heer D, et al. Targeting neuronal lysosomal dysfunction caused by \u03b2-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct. Nat Commun. 2023;14:2057.<\/p>\n<\/li>\n

  • \n

    den Heijer J, Cullen V, Quadri M, Schmitz A, Hilt D, Lansbury P, Berendse H, de Berg W, de Bie R, Boertien J, et al. A large-scale full GBA1 gene screening in Parkinson\u2019s disease in the Netherlands: 18 novel and 1 \u201cDutch\u201d variant. Movement Disord. 2020;35:S197\u20138.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson\u2019s disease. Ann Neurol. 2004;56:149\u201362.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Lee HJ, Suk JE, Bae EJ, Lee SJ. Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem Biophys Res Commun. 2008;372:423\u20138.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Bi M, Du X, Jiao Q, Chen X, Jiang H. Expanding the role of proteasome homeostasis in Parkinson\u2019s disease: beyond protein breakdown. Cell Death Dis. 2021;12:154.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Sorrentino ZA, Giasson BI. The emerging role of alpha-synuclein truncation in aggregation and disease. J Biol Chem. 2020;295:10224\u201344.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Zhang Z, Kang SS, Liu X, Ahn EH, Zhang Z, He L, Iuvone PM, Duong DM, Seyfried NT, Benskey MJ, et al. Asparagine endopeptidase cleaves alpha-synuclein and mediates pathologic activities in Parkinson\u2019s disease. Nat Struct Mol Biol. 2017;24:632\u201342.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Ahn EH, Kang SS, Liu X, Chen G, Zhang Z, Chandrasekharan B, Alam AM, Neish AS, Cao X, Ye K. Initiation of Parkinson\u2019s disease from gut to brain by delta-secretase. Cell Res. 2020;30:70\u201387.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Beyer K, Lao JI, Carrato C, Mate JL, Lopez D, Ferrer I, Ariza A. Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies. Neuropathol Appl Neurobiol. 2004;30:601\u20137.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Beyer K, Domingo-Sabat M, Lao JI, Carrato C, Ferrer I, Ariza A. Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics. 2008;9:15\u201323.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Quintin S, Lloyd GM, Paterno G, Xia YX, Sorrentino Z, Bell BM, Gorion KM, Lee EB, Prokop S, Giasson BI. Cellular processing of \u03b1-synuclein fibrils results in distinct physiological C-terminal truncations with a major cleavage site at residue Glu 114. J Biol Chem. 2023;299:104912.<\/p>\n<\/li>\n

  • \n

    Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, Muller V, Odoy S, Fujiwara H, Hasegawa M, et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest. 2002;110:1429\u201339.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Choi SG, Tittle T, Garcia-Prada D, Kordower JH, Melki R, Killinger BA. Alpha-synuclein aggregates are phosphatase resistant. Acta Neuropathol Commun. 2024;12: 84.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Dhavale DD, Barclay AM, Borcik CG, Basore K, Berthold DA, Gordon IR, Liu J, Milchberg MH, O\u2019Shea JY, Rau MJ, et al. Structure of alpha-synuclein fibrils derived from human Lewy body dementia tissue. Nat Commun. 2024;15:2750.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Fan Y, Sun Y, Yu W, Tao Y, Xia W, Liu Y, Zhao Q, Tang Y, Sun Y, Liu F, et al. Conformational change of alpha-synuclein fibrils in cerebrospinal fluid from different clinical phases of Parkinson\u2019s disease.\u00a0Structure. 2023;31:78\u201387.e5.<\/p>\n<\/li>\n

  • \n

    Li Y, Zhao C, Luo F, Liu Z, Gui X, Luo Z, Zhang X, Li D, Liu C, Li X. Amyloid fibril structure of alpha-synuclein determined by cryo-electron microscopy. Cell Res. 2018;28:897\u2013903.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Frey L, Ghosh D, Qureshi BM, Rhyner D, Guerrero-Ferreira R, Pokharna A, Kwiatkowski W, Serdiuk T, Picotti P, Riek R, Greenwald J. On the pH-dependence of \u03b1-synuclein amyloid polymorphism and the role of secondary nucleation in seed-based amyloid propagation. Elife. 2024;12:RP93562.<\/p>\n<\/li>\n

  • \n

    Klioueva NM, Rademaker MC, Huitinga I. Design of a European code of conduct for brain banking. Handb Clin Neurol. 2018;150:51\u201381.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n","protected":false},"excerpt":{"rendered":"Maroteaux L, Campanelli JT, Scheller RH. Synuclein – a neuron-specific protein localized to the nucleus and presynaptic nerve-terminal.…\n","protected":false},"author":2,"featured_media":154985,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[78],"tags":[90543,90545,18,135,19,17,90544,10047,76051,3267,5801,13128,90546],"class_list":{"0":"post-154984","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-alpha-synuclein","9":"tag-c-terminus","10":"tag-eire","11":"tag-health","12":"tag-ie","13":"tag-ireland","14":"tag-lysosome","15":"tag-molecular-medicine","16":"tag-morphology","17":"tag-neurology","18":"tag-neurosciences","19":"tag-parkinsons","20":"tag-truncation"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/115468024112181950","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/154984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=154984"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/154984\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/154985"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=154984"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=154984"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=154984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}